Business Wire

MA-HARVEY-PERFORMANCE

15.7.2024 15:00:31 CEST | Business Wire | Press release

Share
Harvey Performance Company Acquires ATA, Bringing an International Platform for Continued Growth and Expansion

Harvey Performance Company (“Harvey Performance” or the “company”), a leading provider of specialized cutting tools for precision machining applications, today announced the acquisition of ATA. Harvey Performance serves the market through industry-leading brands Harvey Tool, Helical Solutions, Micro 100, Titan USA, CoreHog, and Valor Holemaking. ATA is an Ireland-based precision engineering multinational and the parent company of the Karnasch, SGSPRO, ATA Tools, Van Hoorn Carbide, Industrial Tooling Corporation (“ITC”), and Garryson brands.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715286290/en/

“We couldn’t be more excited about welcoming ATA to the Harvey Performance family,” said Brian Lavelle, Chief Executive Officer of Harvey Performance Company. “This acquisition represents a milestone in the proud history of the company and further establishes our integrated, international business comprised of distinctive brands and product lines.”

Since its inception as a family business in 1963, ATA has remained steadfast in its dedication to manufacturing, supplying, and distributing tools of exceptional quality. Today, it boasts a product offering exceeding 25,000 precision industrial cutting tools which it supplies to leading manufacturing industries, including aerospace, power generation, electronics, and more. ATA –which is headquartered in Ireland and has additional operating locations in the United Kingdom, United States, Germany, The Netherlands, and Switzerland – engineers, manufactures, and distributes its products globally from its seven manufacturing facilities, worldwide.

“We were immediately impressed by ATA, its global team and tremendous collection of brands,” Lavelle said. “Like all Harvey Performance brands, ATA brands have an established reputation for providing outstanding customer service and a dedication to manufacturing the industry’s highest quality products.”

Harvey Performance and ATA are both established leaders in their respective geographies, and the acquisition is expected to create a powerful combination across North America and Europe. The acquisition will bring an outstanding international platform on which Harvey Performance can continue to grow and expand. The ATA management team will continue to drive business for the company outside of the US.

“This acquisition presents great potential for Harvey Performance,” said Harvey Performance Company Senior Vice President of Sales Jerry Gleisner. “It provides Harvey Performance’s North American customers with exposure to some of the best industrial cutting tools that Europe has to offer.”

Peter Cosgrove, CEO of ATA, said, "ATA is delighted to join Harvey Performance Company, with whom we share a unified global vision for the future. We’re focused on expanding Harvey Performance's brands across Europe and beyond while introducing ATA's leading brands to Harvey Performance’s customers. I am honoured to join the Harvey Performance board. Our management team is looking forward to collaborating with our new colleagues, and our primary focus remains on driving business growth globally.”

“We are excited for the many growth opportunities enabled by the combination of Harvey Performance and ATA’s highly complementary offerings and talented leadership teams,” said Ted Rainaud, Managing Director, Berkshire Partners. “This acquisition represents a significant expansion of Harvey Performance’s product offering and geographic presence. We look forward to supporting the continued growth and expansion of the combined business.”

ATA’s investment partners Development Capital and the Ireland Strategic Investment Fund, who invested in 2017 and 2019 respectively, will exit as a result of the transaction.

Andrew Bourg, Co-founder and Director of Development Capital said, “We are delighted to see ATA attract a company the caliber of Harvey Performance, reflecting the success of the vision for the sector by the ATA management team. During the investment period we have been delighted to help ATA scale significantly and develop into an international leader in the cutting tools industry.”

Brian O’Connor, Ireland Strategic Investment Fund said, “ISIF’s investment in ATA is a clear example of its double bottom line mandate in action, investing on a commercial basis to support the scaling of an Irish indigenous business globally, and so supporting economic activity and the creation of high value employment in Ireland. Today’s announcement reflects a strong performance by the ATA team, a positive outcome for the company and a strong investment return for ISIF.”

Piper Sandler acted as exclusive financial advisor to Harvey Performance Company and Berkshire Partners on the acquisition of ATA. Houlihan Lokey acted as exclusive financial advisor to ATA.

About Harvey Performance Company

Harvey Performance Company strives to offer unique and innovative products to solve the industries’ most challenging machining requirements. Its distinct brands, Harvey Tool, Helical Solutions, Micro 100, Titan USA, CoreHog, and Valor Holemaking serve specialty needs and markets with a shared commitment to delivering high quality products and superior service. The brands offer a broad range of products and services that help support machinists, engineers, and CNC programmers while giving their shops a competitive advantage. Harvey Performance Company has a proud history of doing business the right way – offering fast, friendly service; providing comprehensive product support; and treating customers, suppliers, and shareholders in a way that builds strategic, strong, and enduring relationships. For more information, visit www.harveyperformance.com.

About ATA

ATA is an Irish headquartered manufacturer and supplier of precision cutting tools for industrial leaders around the globe. ATA serves over 7,500 customers in 90 countries. ATA was acquired in 2008 by Peter Cosgrove (CEO) and equity investors. Today the business has operating facilities located across Ireland, Germany, Switzerland, the UK, the Netherlands, and the US, and employs close to 500 people. Its leading brands Karnasch, SGSPRO, ATA Tools, Van Hoorn Carbide, and ITC and Garryson, are recognized as industry leaders throughout Europe. For more information, visit www.atagroup.com.

About Berkshire Partners

Berkshire Partners is a 100% employee-owned, multi-sector specialist investor in private and public equity. The firm’s private equity team invests in well-positioned, growing companies across services & industrials, technology & communications, consumer, and healthcare. Since inception, Berkshire Partners has made more than 150 private equity investments and has a strong history of collaborating with management teams to grow the companies in which it invests. The firm's public equity group, Stockbridge, founded in 2007, manages a concentrated portfolio seeking attractive long-term investments. The firm’s Stockbridge and Private Equity teams frequently collaborate and leverage their collective industry expertise across sectors. For additional information, visit www.berkshirepartners.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240715286290/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye